IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

NCT03758781 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer
Recurrent Cancer
Solid Tumor
Renal Cell Carcinoma
Urothelial Carcinoma
NSCLC
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: IRX 2
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute